Krebs Biochemicals & Industries Limited
NSE: KREBSBIO BSE: KREBSBIO
NSE
72.73
0.85 (1.18%)
Prev Close
71.88
Open Price
70.3
Volume
4,056
Today Low / High
70.3 / 72.73
52 WK Low / High
66.12 / 129.07
Range
69 - 76
BSE
71.00
-2.65 (-3.60%)
Prev Close
73.65
Open Price
70.2
Volume
486
Today Low / High
70.2 / 76.43
52 WK Low / High
63.55 / 129
Range
67 - 75
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 72.73 (target range: 69 - 76), reflecting a change of 0.85 (1.18253%). On the BSE, it is listed at 71 (target range: 67 - 75), showing a change of -2.65 (-3.5981%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
06 Oct
70.30
1.82%
03 Oct
70.06
2.60%
01 Oct
71.80
-0.70%
30 Sep
71.21
-0.81%
29 Sep
71.40
-0.29%
26 Sep
73.09
-2.79%
25 Sep
76.40
-3.86%
24 Sep
77.71
-2.24%
23 Sep
78.90
-1.52%
22 Sep
79.49
0.59%
19 Sep
79.00
-0.09%
18 Sep
80.90
-2.69%
17 Sep
79.00
1.06%
16 Sep
75.25
4.27%
15 Sep
78.40
-4.68%
12 Sep
77.90
-3.26%
11 Sep
75.55
2.91%
10 Sep
73.25
3.14%
09 Sep
74.50
-2.26%
08 Sep
72.50
0.14%
Krebs Biochemicals & Industries Limited Graph
Krebs Biochemicals & Industries Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Krebs Biochemicals & Industries Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 72.73, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 71.00 | 71.71 | 64.54 - 78.88 |
| 72.42 | 57.94 - 86.90 | ||
| 73.13 | 51.19 - 95.07 | ||
| Bearish Scenario | 71.00 | 70.29 | 63.26 - 77.32 |
| 69.58 | 55.66 - 83.50 | ||
| 68.87 | 48.21 - 89.53 |
Overview of Krebs Biochemicals & Industries Limited
ISIN
INE268B01013
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
6,641
Market Cap
1,568,101,420
Last Dividend
0
Official Website
IPO Date
2016-10-27
DCF Diff
N/A
DCF
0
Financial Ratios Every Investor Needs
Stock Dividend of KREBSBIO
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2005-09-14 | September 14, 05 | 2.89781 | 3 | 2005-09-16 | 2005-10-01 | 2005-06-09 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 43.31 Cr | 5.56 Cr | 37.76 Cr | 0.8717 | 1.52 Cr | 0.00 Cr | -21.72 Cr | -26.94 Cr | -12.50 | -14.32 Cr | -0.6220 |
| 2024-03-31 | 50.42 Cr | 61.30 Cr | -10.87 Cr | -0.2157 | 0.00 Cr | 0.60 Cr | -15.49 Cr | -19.73 Cr | -9.15 | -8.27 Cr | -0.3913 |
| 2023-03-31 | 52.13 Cr | 27.72 Cr | 24.42 Cr | 0.4684 | 0.00 Cr | 0.86 Cr | -21.94 Cr | -24.69 Cr | -11.45 | -15.16 Cr | -0.4736 |
| 2022-03-31 | 59.70 Cr | 65.47 Cr | -5.76 Cr | -0.0965 | 1.64 Cr | 1.14 Cr | -39.49 Cr | -44.53 Cr | -20.65 | -32.85 Cr | -0.7458 |
| 2021-03-31 | 38.61 Cr | 52.23 Cr | -13.63 Cr | -0.3529 | 1.47 Cr | 0.67 Cr | -23.67 Cr | -28.36 Cr | -14.45 | -16.96 Cr | -0.7346 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 0.14 Cr | 169.04 Cr | 315.27 Cr | -146.2388 Cr | 212.21 Cr | 212.07 Cr | 6.03 Cr | 146.47 Cr | 0.00 Cr | 0.00 Cr | 2.85 Cr | 103.5260 Cr |
| 2024-03-31 | 0.14 Cr | 178.17 Cr | 297.39 Cr | -119.2167 Cr | 238.68 Cr | 238.61 Cr | 10.24 Cr | 149.74 Cr | 0.00 Cr | 0.00 Cr | -0.47 Cr | 61.8339 Cr |
| 2023-03-31 | 0.09 Cr | 174.98 Cr | 274.44 Cr | -99.4623 Cr | 183.24 Cr | 183.15 Cr | 12.36 Cr | 149.05 Cr | 0.00 Cr | 0.00 Cr | 2.09 Cr | 49.1047 Cr |
| 2022-03-31 | 0.03 Cr | 189.81 Cr | 264.90 Cr | -75.0932 Cr | 188.10 Cr | 188.07 Cr | 25.86 Cr | 144.93 Cr | 0.00 Cr | 0.00 Cr | 0.04 Cr | 78.0640 Cr |
| 2021-03-31 | 0.71 Cr | 159.22 Cr | 201.95 Cr | -42.7329 Cr | 111.14 Cr | 125.55 Cr | 16.89 Cr | 128.21 Cr | 0.00 Cr | 0.00 Cr | 0.04 Cr | 48.1924 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | -7.8910 Cr | -4.9696 Cr | 12.8648 Cr | -11.4542 Cr | 0.0042 Cr | 0.1416 Cr | -3.5632 Cr | -26.9240 Cr | 18.7789 Cr | 0.0000 Cr | 3.7649 Cr |
| 2024-03-31 | 2.3040 Cr | -7.8167 Cr | 5.5641 Cr | -7.0501 Cr | 0.0516 Cr | 0.1374 Cr | -9.4150 Cr | -19.7284 Cr | 10.2535 Cr | 0.0000 Cr | 2.1492 Cr |
| 2023-03-31 | -24.7132 Cr | -12.6450 Cr | 37.3433 Cr | -35.5836 Cr | -0.0148 Cr | 0.0858 Cr | -10.8704 Cr | -24.6919 Cr | 40.3165 Cr | 0.0000 Cr | 13.6170 Cr |
| 2022-03-31 | -17.2162 Cr | -22.8995 Cr | 39.5056 Cr | -40.7363 Cr | -0.6101 Cr | 0.1006 Cr | -23.5201 Cr | -44.5268 Cr | 32.3835 Cr | 0.0000 Cr | -8.9622 Cr |
| 2021-03-31 | -14.5748 Cr | -22.5493 Cr | 37.6605 Cr | -40.0812 Cr | 0.5364 Cr | 0.7107 Cr | -25.5064 Cr | -28.3586 Cr | 33.4906 Cr | 0.0000 Cr | -1.6049 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 5.48 Cr | 0.29 Cr | 5.19 Cr | 0.9472 | -3.69 Cr | -5.32 Cr | -2.47 | -2.08 Cr | -0.9714 |
| 2025-03-31 | 6.10 Cr | 0.57 Cr | 5.53 Cr | 0.9071 | -6.98 Cr | -8.27 Cr | -3.84 | -5.07 Cr | -1.3554 |
| 2024-12-31 | 11.47 Cr | 1.31 Cr | 10.16 Cr | 0.8858 | -6.43 Cr | -7.74 Cr | -3.59 | -4.46 Cr | -0.6749 |
| 2024-09-30 | 12.86 Cr | 2.42 Cr | 10.43 Cr | 0.8117 | -4.42 Cr | -5.76 Cr | -2.67 | -2.62 Cr | -0.4481 |
| 2024-06-30 | 12.89 Cr | 1.26 Cr | 11.63 Cr | 0.9024 | -3.89 Cr | -5.17 Cr | -2.40 | -2.16 Cr | -0.4012 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 0.14 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 146.24 Cr |
| 2025-03-31 | 0.14 Cr | 0.20 Cr | 0.34 Cr | 0.05 Cr | 6.03 Cr | 10.26 Cr | 146.47 Cr | 169.04 Cr | 315.27 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 0.14 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 130.15 Cr |
| 2024-09-30 | 0.14 Cr | 11.06 Cr | 11.21 Cr | 2.57 Cr | 7.73 Cr | 26.21 Cr | 147.19 Cr | 185.20 Cr | 315.35 Cr |
| 2024-06-30 | 0.00 Cr | 0.00 Cr | 0.14 Cr | 0.00 Cr | 0.00 Cr | 0.14 Cr | 0.00 Cr | 0.00 Cr | 119.22 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | -5.32 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | -8.27 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | -7.74 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | -5.76 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | -5.17 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2019-01-31 | January 31, 19 | 207:200 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,654.70 | ₹3,970,173,579,881.00 | ₹1,756,767.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹5,826.50 | ₹1,546,757,529,018.00 | ₹196,212.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,526.00 | ₹1,193,357,070,000.00 | ₹376,267.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,248.60 | ₹1,039,299,991,350.00 | ₹1,880,883.00 |
| Mankind Pharma Limited | MANKIND | ₹2,456.30 | ₹1,013,858,678,987.00 | ₹377,582.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹994.65 | ₹1,000,846,232,849.00 | ₹364,823.00 |
| Lupin Limited | LUPIN | ₹1,937.30 | ₹884,877,017,676.00 | ₹1,001,317.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,494.00 | ₹656,890,110,000.00 | ₹106,173.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,096.50 | ₹636,848,979,620.00 | ₹645,374.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,971.80 | ₹556,443,555,186.00 | ₹346,577.00 |
| Laurus Labs Limited | LAURUSLABS | ₹863.00 | ₹465,868,887,837.00 | ₹1,494,281.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,323.20 | ₹335,701,421,258.00 | ₹85,707.00 |
| Cohance Lifesciences Limited | COHANCE | ₹869.70 | ₹332,718,641,658.00 | ₹155,406.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,431.30 | ₹303,755,982,631.00 | ₹100,950.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,658.80 | ₹259,761,841,253.00 | ₹270,889.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,414.50 | ₹235,362,500,000.00 | ₹23,894.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,429.20 | ₹232,223,277,589.00 | ₹428,259.00 |
| Eris Lifesciences Limited | ERIS | ₹1,607.20 | ₹218,922,423,989.00 | ₹47,179.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹15,106.00 | ₹193,808,303,234.00 | ₹19,762.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹906.35 | ₹178,154,987,437.00 | ₹67,592.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,096.70 | ₹173,882,644,813.00 | ₹72,025.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,021.40 | ₹153,650,042,294.00 | ₹42,984.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹815.15 | ₹146,001,410,531.00 | ₹337,915.00 |
| Granules India Limited | GRANULES | ₹552.70 | ₹134,109,181,833.00 | ₹549,140.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Procter & Gamble Health Limited | PGHL | ₹6,201.00 | ₹102,932,767,782.00 | ₹16,453.00 |
| Strides Pharma Science Limited | STAR | ₹834.10 | ₹76,881,260,747.00 | ₹283,085.00 |
| FDC Limited | FDC | ₹465.65 | ₹75,812,515,615.00 | ₹113,533.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹829.95 | ₹75,220,832,622.00 | ₹152,926.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹377.45 | ₹73,822,356,449.00 | ₹119,629.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.29 | ₹50,554,870,224.00 | ₹683,471.00 |
| Innova Captab Limited | INNOVACAP | ₹832.25 | ₹47,625,447,160.00 | ₹23,268.00 |
| Suven Life Sciences Limited | SUVEN | ₹209.40 | ₹45,657,721,952.00 | ₹147,288.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹499.30 | ₹45,571,111,000.00 | ₹135,801.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹131.91 | ₹42,807,642,673.00 | ₹181,574.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹742.50 | ₹37,658,935,463.00 | ₹61,065.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,252.40 | ₹37,252,477,386.00 | ₹5,835.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹354.70 | ₹35,570,204,878.00 | ₹16,230.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹487.00 | ₹34,287,600,250.00 | ₹11,723.00 |
| Hikal Limited | HIKAL | ₹253.10 | ₹31,207,419,825.00 | ₹196,519.00 |
| IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹103.87 | ₹30,488,702,464.00 | ₹1,844,372.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹48.73 | ₹26,701,783,752.00 | ₹1,385,993.00 |
| Alembic Limited | ALEMBICLTD | ₹102.14 | ₹26,227,695,912.00 | ₹175,157.00 |
| Solara Active Pharma Sciences Limited | SOLARA | ₹612.00 | ₹26,173,985,400.00 | ₹53,814.00 |
| Indoco Remedies Limited | INDOCO | ₹284.00 | ₹26,173,839,020.00 | ₹31,975.00 |
Key Executives
Chief Financial Officer
Mr. Ritesh Jain
Gender: male
Year Born:
Company Secretary & Compliance Officer
Mr. Rakesh R. Kalbate
Gender: male
Year Born:
MD, Chief Executive Officer & Director
Mr. Jitendra Rameshchandra Shah
Gender: male
Year Born: 1968
FAQs about Krebs Biochemicals & Industries Limited
Who is the CEO of the company?
The CEO is Jitendra Rameshchandra Shah.
What is the current market price of the stock?
The current price is ₹72.73.
What is the 52-week price range?
The range is ₹66.12-129.07.
What is the market capitalization of the company?
The market capitalization is ₹156.81 crores.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is -5.79.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Krebs Biochemicals & Industries Limited (ISIN: INE268B01013) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹156.81 crores and an average daily volume of 6,641 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.